Weed Inc(OTCMKTS:BUDZ) has seen a surge northbound in recent weeks as pot stocks heat up across the board and once again light up the OTCBB.
In December BUDZ announced its first of many cultivar DNA sequencing tests have been perfected and finalized. WEED’s team of scientists is currently going thru the analytics evaluation and reports are forthcoming. ”During this time our team designed, tested, and refined standard operating procedures for efficient DNA isolation and sequencing of Cannabis genomes. Extensive bioinformatics analysis of repeatable and variable regions has been performed on newly-generated DNA sequencing data of 26 landrace cultivars and several publicly available genomes.” stated CEO, Glenn E Martin.
Weed Inc bills itself as a USA-based alternative reporting public company. WEED Inc. is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brand. WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments and medical cures utilizing the Cannabaceae plant family. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act, and meets all standards of international law for WEED, Inc. subsidiaries in foreign locations.
WEED operates a wholly-owned subsidiary Sangre AT, LLC which is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. Sangre AgroTech’s world-respected team provides decades of expertise and innovation in the fields of genetics, plant biology, plant pathology, phytoecology, and sustainable and environmentally sound agricultural practices. Using annotated genomic data and newly generated phenotypic data, Sangre AgroTech will identify and isolate regions of the genome related to growth, synthesis of desired molecules, drought and pest resistance. This complex data set will be utilized in a breeding program to generate and establish new hybrid cultivars which exemplify the traits desired by the medical community.
To Find out the inside Scoop on BUDZ Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
In July of last year Sangre Agrotech completed their acquisition of property in La Veta, CO., as stated in our last press release for development of its Cannabis genomic research facility, The Sangre Bioscience Center. La Veta, located in southern Colorado’s Spanish Peaks region, is the new home for Sangre AT, LLC (dba “Sangre AgroTech”), the Company’s wholly-owned subsidiary. Sangre AgroTech has begun its 5-Year, $15+ million Cannabis Genomic Study to complete a global genomic classification of the Cannabis plant genus.
The site includes a 10,000+ sq. ft. building that will house the genomic research facility, a 4,000+ square foot building for plant product analytics and plant product extraction, a 3,500 sq. ft. corporate office center, and 25 RV slots with full water and electric, which the company plans to convert into a series of small research pods. This acquisition provides WEEDS’ Sangre AgroTech with the opportunity to expand its research mission through the construction of additional research laboratories and cloning facilities.
The press release on December states:
The final goal of the genomic studies is the development of a database for the Comprehensive Molecular Breeding Platform connecting cultivar’s properties (e.g., THC, CBD, disease resistance, acceptable growth conditions) and their genetic signatures. To achieve these goals, WEED Inc is planning to design a genotyping assay to determine the cultivar’s genetic profile and be able to perform comprehensive molecular-based breeding of thousands of cultivars in a quick and inexpensive way. The Company expects that this data, in concert with cultivar’s chemical profiles, will allow it to computationally predict Quantitative Trait Loci (a region of the genome that correlates to plant’s traits). A database of these genomic regions, QTLs, and associated chemical profiles comprehensive knowledge base will be the key to create ”designer” cultivars.
we have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $169 million market valuation BUDZ has $794k in the treasury, minimal assets and no revenues to date. BUDZ is an exciting story deceloping in small caps; the Company is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization whos wholly-owned subsidiary Sangre AT, LLC acquired a research facility and has begun its 5-Year, $15+ million Cannabis Genomic Study to complete a global genomic classification of the Cannabis plant genus.That being said shareholders are anxiously waiting for more information from the Company especially concerning the build out of their facility. We will be updating on BUDZ when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with BUDZ.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in BUDZ either long or short and we have not been compensated for this article.